Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06337097 · ClinicalTrials.gov registry record · NA
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
A NA study of Immune Checkpoint Therapy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 980
- Enrollment target
- 1
- Study location
NCT06337097: Recruiting NA study of Immune Checkpoint Therapy, sponsored by M.D. Anderson Cancer Center.
NCT06337097 is a NA study of Immune Checkpoint Therapy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 980 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06337097, a NA study of Immune Checkpoint Therapy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 980 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
Conditions Studied
Interventions
- OTHER Standard of care
- DIAGNOSTIC_TEST Troponin surveillance
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 980 participants |
| Start Date | 2024-02-02 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT06337097 shows while recruiting
NCT06337097 is an interventional study that assigns participants to a tested intervention. The registered 980 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Immune Checkpoint Therapy appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.
NCT06337097 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06337097 about?
NCT06337097 is a clinical study titled "STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy". To learn if monitoring blood levels of heart injury (troponin levels) in cancer participants treated with immune checkpoint inhibitors will lead to decreased heart-related side effects.
What is the current status of trial NCT06337097?
This trial is currently recruiting. It is a NA study. The enrollment target is 980 participants. The study started on 2024-02-02. Estimated completion is 2028-12-31.
What conditions does trial NCT06337097 study?
This clinical trial studies the following conditions: Immune Checkpoint Therapy.
What interventions are being tested in trial NCT06337097?
The interventions under investigation include: Standard of care (OTHER), Troponin surveillance (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06337097?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06337097 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Checkpoint Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06337097's enrollment target sits among peer trials
980 122nd of 2000 higher than 1,879 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07070232 · 980 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- NCT07184931 · 980 participants · Phase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- NCT07184996 · 980 participants · Phase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- NCT06959095 · 981 participants · Phase 3
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI